According to the American Cancer Society, pancreatic cancer has a five-year survival rate of less than 15 percent and is the fourth leading cause of death from cancer in the United States. Present-day chemotherapy treatments attempt to lengthen the lives of patients but are often unsuccessful due to the nature of the disease. Doxorubicin and Gemcitabine are already commonly prescribed as pancreatic cancer treatments while Thermodox®, a lysolipid thermally-sensitive liposome (LTSL) technology, is still undergoing clinical trials. LTSLs encapsulate Doxorubicin releasing the drug when the agent is exposed to temperatures greater than 40 degrees C. The goal of this study is to compare the in vitro cytotoxicity of four chemotherapeutic conditions: unheated Thermodox®, heated Thermodox®, Doxorubicin, and Gemcitabine. Varying concentrations of each drug condition are applied to LMP, PANC-1, and Mia-PaCa cell lines, which originate from mouse and human pancreas carcinoma. The remaining post-treatment viable cells and relevent controls are then stained with a fluorescent dye (Hoechst 33342) and analyzed by a fluorescent plate reader, from which cell death can be determined. Preliminary results show that that unheated Thermodox is not toxic to cells, and heated Thermodox®, Doxorubicin, and Gemcitabine is toxic to cells. The results of this experiment can lead to greater knowledge of the cytotoxicity of current chemotherapy agents as well as new technologies in cancer treatment.